Family of selectins in non-alcoholic fatty liver disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: to study relationship of selectins with features of course of non-alcoholic fatty liver disease (NAFLD). Material and methods. 208 patients with NAFLD (107 men, 101 women) aged from 18 to 65 years were included in study. In 64,4% of cases disease was characterized by absence of increase in activity of cytolytic enzymes, in 35,6% of patients there was variant with increase in activity of alanine (AlAT) and aspartic (AsAT) aminotransferases. Patients were more likely to have mild (40,8%) and moderate (38,5%) hepatic steatosis. The metabolic syndrome was detected in 59,1% of NAFLD cases. Results. Statistically significant increase of levels of E-, P- and L-selectins in blood was present in NAFLD. In patients with increased activity of aminotransferases concentration of E-selectin in blood was higher than in those with normal levels of AsAT and AlAT. The comorbidity of NAFLD and metabolic syndrome was characterized by decrease in levels of L-selectin in blood. With increasing severity of liver steatosis levels of E-selectin in blood increased, and levels of L-selectin decreased, reaching extreme values in steatosis of 3rd degree. The threshold values of E-selectin >51 ng/ml had moderate accuracy (74,6%) in distinguishing between the norm and NAFLD. Conclusion. Increased levels of selectins in blood is interrelated with variants of course of NAFLD. Association of selectins imbalance with severity of disease indicates clinical and pathogenetic significance of endothelial mediators in non-alcoholic fatty liver disease.

Full Text

Restricted Access

About the authors

Pavel V. Koroy

Stavropol State Medical University of the Ministry of Healthcare of Russia

Email: paule75@yandex.ru
MD, professor of Department of hospital therapy

Yulia A. Kravchenko

Municipal Polyclinic No. 9, Stavropol

Email: rudenchy@mail.ru
therapist

Alexander V. Yagoda

Stavropol State Medical University of the Ministry of Healthcare of Russia

Email: lexander.yagoda@gmail.com
MD, professor, head of Department of hospital therapy

References

  1. Haas J.T., Francque S., Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016; 78: 181-205. doi: 10.1146/annurev-physiol-021115-105331.
  2. Hammoutene A., Rautou P.E. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J. Hepatol. 2019; 70(6): 1278-91. doi: 10.1016/j.jhep.2019.02.012.
  3. Hammoutene A., Biquard L., Lasselin J. et al. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. J. Hepatol. 2020; 72(3): 528-38. doi: 10.1016/j.jhep.2019.10.028.
  4. Сляднев С.А., Корой П.В. Потенциал адгезинов в диагностике неалкогольной жировой болезни печени. Медицинский вестник Северного Кавказа. 2017; 1: 98-99. doi: 10.14300/ mnnc.2017.12028.
  5. Ягода А.В., Корой П.В., Сляднев С.А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 2: 45-51.
  6. Bilgir F., Bilgir O., Calan M. et al. The levels of soluble intercellular adhesion molecule, vascular adhesion molecule and se-selectin levels in patients with non-alcoholic fatty liver disease. J. Autacoids Horm. 2015; 4(1): 108. doi: 10.4172/2161-0479.1000108.
  7. Cao Y., Li L. Relationship of non-alcoholic steatohepatitis with arterial endothelial function and atherosclerosis. Zhonghua Gan Zang Bing Za Zhi. 2014; 22(3): 205-08. doi: 10.3760/cma.j.issn.1007-3418.2014.03.012.
  8. Fricker Z.P., Pedley A., Massaro J.M. et al. Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham Heart Study. Clin Gastroenterol Hepatol. 2019; 17(6): 1157-64. doi: 10.1016/j.cgh.2018.11.037.
  9. Bertola A., Park O., Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: A critical role for E-selectin. Hepatology. 2013; 58(5): 1814-23. doi: 10.1002/hep.26419.
  10. Dawson A.J., Sathyapalan T., Smithson J.A. et al. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014; 80(6): 843-49. doi: 10.1111/ cen.12258.
  11. Ustyol A., Ustyol E. A., Gurdol F., Kokali F. P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease. Scand J. Clin Lab Invest. 2017; 77(3): 205-09. doi: 10.1080/00365513.2017.1292363.
  12. Комшилова К.А. Абдоминальное ожирение и неалкогольная жировая болезнь печени: клинико-лабораторные и морфологические сопоставления: автореф. дис. канд. мед. наук. М. 2015; 26 с.
  13. Mosa T.E., Shehatta A.S., Khayyal A.A. et al. High serum levels of endothelial adhesion molecules E-selectin, ICAM-1 and VCAM in fatty liver patients. Asian J. Biochem. 2011; 6(2): 160-70. doi: 10.3923/ajb.2011.160.170.
  14. Simons N., Bijnen M., Wouters K.A.M. et al. The endothelial function biomarker soluble E-selectin is associated with nonalcoholic fatty liver disease. Liver Int. 2020; 40(5): 1079-88. doi: 10.1111/liv.14384.
  15. Thakur M. L., Sharma S., Kumar A. et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012; 223(2): 507-11. doi: 10.1016/j.atherosclerosis.2012.06.005.
  16. Kuo C.Y., Day Y.J., Hung L.M. The impact of P-selectin deficiency on obesity-associated non-alcoholic fatty liver disease. FASEB J. 2014; 28(1): 1116.8.
  17. Chiang C.H., Huang P.H., Chung F.P. et al. Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. PLoS One. 2012; 7: e31799. doi: 10.1371/journal.pone.0031799.
  18. Журавлева Л.В., Кривоносова Е.М. Влияние сочетанной терапии альфа-липоевой кислотой и бенфотиамином на течение неалкогольной жировой болезни печени. Практикуючий лкар. 2014; 4: 42-47.
  19. Grander C., Grabherr F., Moschen A.R., Tilg H. Non-alcoholic fatty liver disease: cause or effect of metabolic syndrome. Visc Med. 2016; 32(5): 329-34. doi: 10.1159/000448940.
  20. Chong L., Laight D., Fowell A.J. et al. PWE-133 Vascular inflammation is associated with endothelial dysfunction and oxidative stress in patients with non-alcoholic fatty liver disease. Gut. 2015; 64: A271-A272. doi: 10.1136/gutjnl-2015-309861.582.
  21. Bae Y.J., Kim S.H., Chung J.H. et al. Evaluation of adiposity-related biomarkers as metabolic syndrome indicators. Clin Nutr Res. 2013; 2(2): 91-99. doi: 10.7762/cnr.2013.2.2.91.
  22. Корой П.В., Сляднев С.А., Ягода А.В. Взаимосвязь метаболического синдрома с молекулами адгезии при неалкогольной жировой болезни печени. Медицинский вестник Северного Кавказа. 2020; 1: 23-27. doi: https://doi.org/10.14300/mnnc.2020.15004.
  23. Akbas H., Oguz E., Tabur S. et al. ICAM-1 E469K and E-Selectin S128R polymorphisms with non-diabetic metabolic syndrome. J. Harran University Medical Faculty. 2015; 12(1): 58-66.
  24. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. с соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 2: 24-42. doi: https://doi.org/10.22416/1382-4376-2016-26-2-24-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies